A novel antimicrobial peptide derived from human BPIFA1 protein protects against Candida albicans infection.

IF 2.8 4区医学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Innate Immunity Pub Date : 2022-02-01 DOI:10.1177/17534259221080543

Nan Hu, Xi-Ming Mo, Shi-Na Xu, Hao-Neng Tang, Ying-Hui Zhou, Long Li, Hou-De Zhou

{"title":"A novel antimicrobial peptide derived from human BPIFA1 protein protects against Candida albicans infection.","authors":"Nan Hu, Xi-Ming Mo, Shi-Na Xu, Hao-Neng Tang, Ying-Hui Zhou, Long Li, Hou-De Zhou","doi":"10.1177/17534259221080543","DOIUrl":null,"url":null,"abstract":"Bactericidal/permeability-increasing fold containing family A, member 1 (BPIFA1) is an innate immunity defense protein. Our previous studies proved its antibacterial and antiviral effects, but its role in fungi remains unknown. The study aimed to identify antifungal peptides (AFP) derived from BPIFA1, and three antimicrobial peptides (AMP1-3) were designed. The antifungal effects were proved by growth inhibition assay. AMP3 activity was confirmed by germ tube growth experiment and XTT assay. Its effects on cell wall and membrane of Candida albicans were assessed by tannic acid and Annexin V-FITC/PI double staining, respectively. Additionally, scanning electron microscope (SEM) and transmission electron microscopy (TEM) were used for morphological and ultrastructural observation. The expression of ALS1, EAP1, and SUN41 was tested by qPCR. Ultimately, three AMPs could fight against C. albicans in vitro, and AMP3 was highly effective. It functioned by destroying the integrity of cell wall and normal structure of cell membrane. It also inhibited biofilm formation of C. albicans. In addition, AMP3 down-regulated the expression of ALS1, EAP1, and SUN41, those are known to be involved in virulence of C. albicans. Altogether, the study reported successful development of a novel AFP, which could be used as a new strategy for antifungal therapy.","PeriodicalId":13676,"journal":{"name":"Innate Immunity","volume":"28 2","pages":"67-78"},"PeriodicalIF":2.8000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/6d/10.1177_17534259221080543.PMC9058375.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Innate Immunity","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1177/17534259221080543","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Bactericidal/permeability-increasing fold containing family A, member 1 (BPIFA1) is an innate immunity defense protein. Our previous studies proved its antibacterial and antiviral effects, but its role in fungi remains unknown. The study aimed to identify antifungal peptides (AFP) derived from BPIFA1, and three antimicrobial peptides (AMP1-3) were designed. The antifungal effects were proved by growth inhibition assay. AMP3 activity was confirmed by germ tube growth experiment and XTT assay. Its effects on cell wall and membrane of Candida albicans were assessed by tannic acid and Annexin V-FITC/PI double staining, respectively. Additionally, scanning electron microscope (SEM) and transmission electron microscopy (TEM) were used for morphological and ultrastructural observation. The expression of ALS1, EAP1, and SUN41 was tested by qPCR. Ultimately, three AMPs could fight against C. albicans in vitro, and AMP3 was highly effective. It functioned by destroying the integrity of cell wall and normal structure of cell membrane. It also inhibited biofilm formation of C. albicans. In addition, AMP3 down-regulated the expression of ALS1, EAP1, and SUN41, those are known to be involved in virulence of C. albicans. Altogether, the study reported successful development of a novel AFP, which could be used as a new strategy for antifungal therapy.

Abstract Image

查看原文本刊更多论文

从人BPIFA1蛋白中提取的一种新型抗菌肽可预防白色念珠菌感染。

含有A家族成员1的杀菌/增透蛋白(BPIFA1)是一种天然免疫防御蛋白。我们之前的研究证实了它的抗菌和抗病毒作用，但它在真菌中的作用尚不清楚。本研究旨在鉴定BPIFA1衍生的抗真菌肽(AFP)，并设计了3个抗菌肽(AMP1-3)。生长抑制实验证实了其抑菌作用。胚管生长实验和XTT法证实了AMP3活性。单宁酸双染色法和Annexin V-FITC/PI双染色法分别评价其对白色念珠菌细胞壁和细胞膜的影响。并采用扫描电镜(SEM)和透射电镜(TEM)进行形态学和超微结构观察。采用qPCR检测ALS1、EAP1和SUN41的表达。最终，3种AMPs均能在体外对抗白色念珠菌，其中AMP3效果较好。它通过破坏细胞壁的完整性和细胞膜的正常结构发挥作用。它还能抑制白色念珠菌生物膜的形成。此外，AMP3还下调了ALS1、EAP1和SUN41的表达，这些基因已知与白色念珠菌的毒力有关。总之，该研究报告了一种新型AFP的成功开发，它可以用作抗真菌治疗的新策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Innate Immunity 生物-免疫学

CiteScore

7.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Innate Immunity is a highly ranked, peer-reviewed scholarly journal and is the official journal of the International Endotoxin & Innate Immunity Society (IEIIS). The journal welcomes manuscripts from researchers actively working on all aspects of innate immunity including biologically active bacterial, viral, fungal, parasitic, and plant components, as well as relevant cells, their receptors, signaling pathways, and induced mediators. The aim of the Journal is to provide a single, interdisciplinary forum for the dissemination of new information on innate immunity in humans, animals, and plants to researchers. The Journal creates a vehicle for the publication of articles encompassing all areas of research, basic, applied, and clinical. The subject areas of interest include, but are not limited to, research in biochemistry, biophysics, cell biology, chemistry, clinical medicine, immunology, infectious disease, microbiology, molecular biology, and pharmacology.